Recent nieuws


13 september 2021
Zorg Instituut Nederland (ZIN) geeft positief advies voor vergoeding van de Oncotype DX Breast Recurrence Score® test

20 mei 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

24 maart 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer


2020 Archief
2019 Archief
2018 Archief
2017 Archief
Making cancer care smarter.™